Vivani Medical's new semaglutide implant shows promise in animal trials, leading to significant weight loss.

Vivani Medical has reported promising results from an animal study of its new semaglutide implant, NPM-139, aimed at managing weight in obese individuals. The study showed rats experienced about 20% weight loss over three months. The implant, designed to be administered once or twice a year, could improve medication adherence and patient convenience for treating obesity and type 2 diabetes.